Shehzad Kamran, MD
Psychiatry · Knoxville, IANPI 1942247739
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 27.2% of the total.
Across 95 payments — averaging $10.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$261
- AbbVie$195
- Johnson & Johnson$174
- Alkermes, Inc.$99
- Vanda Pharmaceuticals Inc.$70
- Sunovion Pharmaceuticals Inc.$63
- plus $95 from 5 others
What the payments were for
- Food & beverage$92897%
- Education$303%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $261 |
| AbbVie | 36 | $195 |
| Johnson & Johnson | 18 | $174 |
| Alkermes, Inc. | 6 | $99 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Sunovion Pharmaceuticals Inc. | 5 | $63 |
| Teva Pharmaceuticals USA, Inc. | 1 | $34 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
How this compares
$958 in reported general payments places this provider in the 75th percentile of 245 psychiatry providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 31 | $199,351 |
| TrintellixVortioxetine Hydrobromide | 272 | $158,329 |
| IngrezzaValbenazine Tosylate | 19 | $151,318 |
| VraylarCariprazine Hcl | 73 | $92,767 |
| RexultiBrexpiprazole | 56 | $85,019 |
| CaplytaLumateperone Tosylate | 44 | $70,412 |
| Invega SustennaPaliperidone Palmitate | 17 | $59,315 |
| AuvelityDextromethorphan Hbr/Bupropion | 28 | $31,242 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $25,044 |
| Clozapine | 214 | $16,670 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 315 | $14,634 |
| VyvanseLisdexamfetamine Dimesylate | 26 | $9,985 |
| Quetiapine Fumarate | 604 | $9,368 |
| Ziprasidone Hcl | 132 | $8,011 |
| Duloxetine Hcl | 381 | $7,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $34 | $199,35131 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $16 | $168,314298 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $12 | $151,31819 claims |
| AbbVieVraylar, Fetzima | $195 | $98,93186 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $261 | $85,01956 claims |
| Johnson & JohnsonInvega Sustenna | $174 | $59,31517 claims |
| Alkermes, Inc.Lybalvi | $99 | $25,04415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 245 psychiatry providers in Iowa.
Other psychiatry in Knoxville
- Charles JennischUrbandale$949K
- Manmohan SinghDes Moines$408K
- Jimmy MascaroOttumwa$361K
- Alan WhittersCedar Rapids$170K
- Donald BlackIowa City$19K
- William CoryellIowa City$18K
- Randall KavalierWest Des Moines$15K
- Dwight SchroederCedar Rapids$13K
- Rodney DeanSioux City$11K
- Peggy NopoulosIowa City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.